

LISTING NOTICE



Issuer	Oxygen Biotherapeutics, Inc. (the Company), a corporation organised and existing under the laws of the State of Delaware (USA); registered office: 2711 Centerville Road, Suite 400, Wilmington, DE 19808; head office: 2530 Meridian Parkway, Suite 3078, Durham, NC 27713, USA.
Secondary Listing / first trading day	Application has been made to the SIX Swiss Exchange Ltd (the SIX Swiss Exchange) for a secondary listing of 28,374,353 shares of common stock of Oxygen Biotherapeutics, Inc. with a par value of USD 0.0001 per share on the SIX Swiss Exchange in accordance with the Main Standard thereof, 23,368,711 of which shares are currently issued and outstanding and 5,005,642 of which shares are to be listed “formally” as conditional capital for issuance upon the exercise of outstanding options, warrants and rights to acquire the Company’s common stock. The shares will be traded in CHF and the first trading day is expected to be June 29, 2010.
Primary listing	The shares of the Company are, and continue to be, listed on NASDAQ-CM under the symbol "OXBT".
Share capital	As of 4 June 2010, there were 23,368,711 shares of common stock outstanding and no shares of preferred stock outstanding. In addition, there are outstanding options, warrants and rights to acquire up to an additional 5,005,642 shares of common stock. The Company’s authorized capital stock consists of 400 mio. shares of common stock, USD 0.0001 par value per share, and 10 mio. shares of preferred stock in one or more series, USD 0.0001 par value per share.
Dividend and distribution rights	Holders of the shares are equally entitled to receive dividends and other distributions declared by the Company with respect to the shares, if any.
Description of common stock	Holders of common stock are entitled to one vote per share on all matters submitted to the stockholders for a vote. There are no cumulative voting rights in the election of directors. The shares of common stock are entitled to share, ratably, in the net assets, if any, of the Company upon liquidation. The stockholders have no preemptive rights to purchase any shares of the Company’s capital stock. The transfer agent for the common stock is Interwest Transfer Company, Salt Lake City, Utah (USA).

Form of the shares Shares of common stock may be issued in certificated or book entry form.

Listing prospectus This Listing Notice does not constitute an issuing prospectus, as defined in Art. 652a of the Swiss Code of Obligations.

In accordance with Art. 14 of the Directive on the Listing of Foreign Companies (DFC), the Regulatory Board of the SIX Swiss Exchange has recognised as the listing prospectus a prospectus, including the documents incorporated by reference, drawn up in connection with the Company's public offering of units (consisting of shares and warrants to purchase shares) conducted subsequent to listing on the primary exchange (NASDAQ), in accordance with the U.S. Securities Act of 1933, amended with the required technical information for the Swiss market.

This listing prospectus and any reference documents can be downloaded on www.oxybiomed.com or obtained from the Company: Oxygen Biotherapeutics, Inc., Attn: Ellen Corliss, 2530 Meridian Parkway, Suite 3078, Durham, NC 27713, USA, Telephone: 800 809-6054, Fax: (919) 806-4417.

This listing prospectus is the sole authoritative source of information on the listing of the shares at the SIX Swiss Exchange. By making a decision to invest in the shares, investors must rely on their own valuation of the Company and the shares, including the merits and risks involved.

Security number: 10728277
ISIN: US69207P2092
Symbol: OXBT

Paying Agent
(Zahlstelle): Bank am Bellevue AG, Seestrasse 16, 8700 Küsnacht ZH, Switzerland,
Telephone +41 44 267 67 67.

29 June 2010

Oxygen Biotherapeutics, Inc.

BANK AM BELLEVUE